Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality

Sean Nicholson, Patricia M. Danzon, Jeffrey S. McCullough

NBER Working Paper No. 9007
Issued in June 2002
NBER Program(s):Corporate Finance, Health Care

Biotechnology companies rely heavily on alliances with pharmaceutical companies to finance their research and development expenditures, and pharmaceutical firms rely heavily on alliances to supplement their internal research and development. Previous studies suggest that asymmetric information may lead to inefficient contracting. We examine the determinants of biotech-pharmaceutical deal prices to determine whether the market for deals between biotech and pharmaceutical companies functions as a well-informed market or whether it is characterized by asymmetric information. We find that inexperienced biotech companies receive substantially discounted payments when signing their first deal. Drugs that are jointly developed are more likely to advance in clinical trials than drugs that are developed by a single company, so the first-deal discount is not consistent with the post-deal performance of these drugs. We also find that biotech companies that sign deals receive substantially higher valuations from venture capitalists and from the public equity market, which implies that the discounts are rational; a biotechnology company that is developing its first product benefits from forming an alliance with a pharmaceutical company because it sends a positive signal to prospective investors.

download in pdf format
   (397 K)

email paper

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w9007

Published: Sean Nicholson, 2005. "Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality," Journal of Business, University of Chicago Press, vol. 78(4), pages 1433-1464, July. citation courtesy of

Users who downloaded this paper also downloaded* these:
Lerner and Merges w6014 The Control of Strategic Alliances: An Empirical Analysis of Biotechnology Collaborations
Danzon, Epstein, and Nicholson w10536 Mergers and Acquisitions in the Pharmaceutical and Biotech Industries
Danzon, Nicholson, and Pereira w9615 Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances
Ravenscraft and Long Paths to Creating Value in Pharmaceutical Mergers
Lee, McCullough, and Town w18025 The Impact of Health Information Technology on Hospital Productivity
NBER Videos

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email:

Contact Us